Success Story: Advancing Targeted Nanomedicine and Biocompatible Drug Delivery Platforms: NIW Approval Secured for a Biomedical Engineering Researcher
Client’s Testimonial:
“Thank you very much for all the great work you have done with my case!”
On September 24th, 2026, we received another EB-2 NIW (National Interest Waiver) approval for a Ph.D. candidate/Graduate Research Assistant in the Field of Biomedical Engineering (Approval Notice).
General Field: Biomedical Engineering
Position at the Time of Case Filing: Ph.D. candidate/Graduate Research Assistant
Country of Origin: Bangladesh
State of Residence at the Time of Filing: Maryland
Approval Notice Date: September 24th, 2026
Processing Time: 2 months, 1 day (Premium Processing Requested)
Case Summary:
The client received approval based on his research in targeted nanomedicine and cancer drug delivery. His proposed endeavor focuses on developing biocompatible nanoparticle-based therapies and advancing them toward clinical scalability and translational use in the United States. The petition highlighted his strong publication and citation record, bridging his previous nanofiber-based drug delivery research with proposed nanomedicine-based targeted drug delivery for cancer treatment, peer-review activity, and ongoing translational research as evidence that he was well positioned to advance this work. USCIS approved the petition without issuing an RFE. This work directly supports U.S. public health goals, strengthens domestic biomedical research infrastructure, and advances federal initiatives in precision medicine.
Academic Contributions and Credentials
To demonstrate that the client was exceptionally well-positioned to advance his endeavor under Matter of Dhanasar, North America Immigration Law Group (Chen Immigration Law Associates) presented a comprehensive evidentiary record highlighting his scientific standing. Notably, at the time of filing, the client did not hold an advanced degree. Instead, he qualified through the Exceptional Ability pathway and five years of professional experience. His relevant credentials included:
- 538 total citations accrued across his published body of work from independent researchers globally
- 8 peer-reviewed journal articles (4 first-authored) and 2 first-authored abstracts
- 5 highly cited publications, including 1 paper ranking in the top 1% and 4 papers ranking in the top 10% most-cited articles in materials science for their respective publication years
- At least 3 completed peer reviews for authoritative scientific journals in biomedical engineering and materials science
- Major federal research grant support funded by prestigious institutions, including the National Institutes of Health (NIH) and the U.S. Department of Veterans Affairs
Rather than presenting raw citation counts as self-evidently sufficient, the petition provided detailed bibliometric contextualization for the USCIS adjudicator. We demonstrated that independent research teams globally actively rely on his nanomaterial processing techniques, polymeric scale-up analyses, and fiber formulation models to advance antimicrobial materials, nanocrystal production, and cancer nanotherapeutics.
NIW Approval and Outlook
The petition was further reinforced by recommendation letters from field experts who confirmed the national importance, clinical necessity, and technical rigor of his nanomedicine research.
"In conclusion, [Client’s] research advances the development of biocompatible nanodrug delivery systems that boost treatment precision and safety for cancer and neurological diseases, ultimately improving patient outcomes and reducing the healthcare burden in the United States."
The petition successfully established that the client's proposed endeavor holds substantial merit and national importance. By synthesizing his publication output, top-tier citation percentiles, federal grant backing, independent reliance, and expert endorsements into a cohesive narrative, we presented a compelling case.
Filed under Direct Premium Processing, USCIS approved the I-140 NIW petition. We congratulate the client on this NIW approval and look forward to his continued contributions to biomedical engineering, nanomedicine, and targeted cancer therapeutics in the United States.